Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer

被引：0
|
作者：
Qifei He
Jiahui Chen
Kai Zhou
Chenggen Jin
Anqiang Wang
Ke Ji
Xin Ji
Ji Zhang
Xiaojiang Wu
Xia Li
Zhaode Bu
Jiafu Ji
机构：
[1] Peking University Cancer Hospital and Institute,Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Karolinska Institutet,Department of Medical Epidemiology and Biostatistics
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4413 / 4422
页数：9
相关论文
共 50 条
  • [41] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [42] Adjuvant treatment for HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (02): : E59 - E59
  • [43] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Danijela Jelovac
    Antonio C. Wolff
    Current Treatment Options in Oncology, 2012, 13 : 230 - 239
  • [44] Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
    Ishii, Takahiro
    Shitara, Kohei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1193 - 1201
  • [45] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Jelovac, Danijela
    Wolff, Antonio C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 230 - 239
  • [46] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [47] Trastuzumab in HER2-Positive Metastatic Gastric Cancer Profile Report
    Croxtall, Jamie D.
    McKeage, Kate
    BIODRUGS, 2011, 25 (04) : 257 - 259
  • [48] Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?
    Santini, Daniele
    Vincenzi, Bruno
    Tonini, Giuseppe
    WOMENS HEALTH, 2006, 2 (01) : 1 - 3
  • [49] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Hudis, CA
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 12 - 13
  • [50] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
12345